Summary Recent studies have shown that elevated levels of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1) in breast cancer correlate with an increased risk of a reduced relapse-free survival time and shortened overall survival times. Urokinase PA and PAI-I are independent prognostic indicators for breast cancer (Goldfarb and Liotta, 1986) . Among the diverse extracellular proteolytic enzymes produced by tumours, urokinase plasminogen activator (uPA) is considered to play a pivotal role in tissue invasion, vascular invasion and formation of metastases (Dano et al., 1985) .
Neoplastic tissues synthesise and secrete proteases which can degrade extracellular matrix (ECM) constituents, and thereby facilitate the migration of malignant cells through anatomical barriers (Goldfarb and Liotta, 1986) . Among the diverse extracellular proteolytic enzymes produced by tumours, urokinase plasminogen activator (uPA) is considered to play a pivotal role in tissue invasion, vascular invasion and formation of metastases (Dano et al., 1985) .
Tumour cells synthesise and secrete uPA as an inactive proenzyme (pro-uPA) (Stump, 1986) , which binds to specific receptors on the cell surface (Vasalli et al., 1985) . After binding, pro-uPA is activated by cathepsin B or plasmin (Kobayashi et al., 1990) . Receptor-bound active uPA converts plasminogen to plasmin. Subsequently, plasmin is also bound to a different receptor on the tumour cell surface (Miles and Plow, 1988) . Plasmin then degrades components of the stroma (e.g. fibrin, fibronectin, proteoglycans, laminin), and may activate procollagenase type IV, which then degrades collagen type IV, a major part of the basement membrane (Dvorak, 1986) . Thus uPA promotes the dissolution of the tumour matrix and the basement membrane, which is a prerequisite for invasion and metastases. This implies that the proteolytic activity of uPA also causes a degradation of vessel walls. Vessel wall dissolution is one of the first steps in neovascularisation (Mahadevan and Hart, 1990) . Furthermore, some ECM molecules become angiogenic after hydrolytic degradation (West et al., 1985 and Kumar 1989) .
Neovascularisation can also be a consequence of fibrin deposition (Liu et al., 1990) because it serves as a migratory matrix for endothelial cells and leucocytes , and because its plasmin-cleaved fragments such as fragment E (Thompson et al., 1992 ) have a strong angiogenic potential. Fibrin deposition results from extravasation and subsequent coagulation of plasma fibrinogen. For extravasation of the large fibrinogen molecule the permeability of the vasculature must be markedly increased . Macrophages can increase vascular permeability by releasing vasoactive substances (Berse et al., 1992) .
Furthermore, it has recently been demonstrated that expression of uPA by macrophages leads to the plasmindependent release of matrix-bound heparan sulphate proteoglycan, basic fibroblast growth factor, and transforming growth factor beta (Falcone et al., 1993 a,b The oestrogen and progesterone receptors were determined by a multipoint dextran-coated charcoal assay.
Tissue extraction
Breast cancer tissue specimens were obtained at surgery and stored at -80'C until extraction. In every case we produced two tissue extracts, one sample was gained from the tumour margin and another one from central portions of the tumour. Deep-frozen specimens of 300-400 mg wet weight were pulverised by conventional mesh graters. The resulting powder was suspended in 1.8 ml of Tris-buffered saline (TBS; 0.002 M Tris-HCl, 0.125 M sodium chloride, pH 8.5) and 0.2 ml of the non-ionic detergent Triton X-100 10% (Sigma, Munich, Germany), yieldihg a 1% Triton X-100 final preparation.
After gentle stirring for 12 h at 4'C, the suspension was subjected to ultra-centrifugation (100 000 g for 60 min, 4°C) in order to separate cell debris, nuclei and all cell membranes. The total protein content of the extract was measured by using a conventional biuret-protein reaction assay. The detergent Triton X-100 present in the tissue extracts does not interfere with the protein determination assay. Urokinase PA and PAI-I were determined in the Triton X 100 extract and calculated per mg of tissue protein.
Laboratory assay
We performed a uPA and a PAI-I ELISA using a commercially available ELISA kit (American Diagnostica, Greenwich CT, USA). Microtitre plates (96 wells) were precoated with monoclonal antibody to human uPA (no. 394; American Diagnostica). An aliquot of 100 ,ul of 1:20 diluted tissue extracts (1% bovine serum albumin; BSA-TBS) and uPA standard were added to microtest wells, and incubated overnight at 4'C in a humid chamber. Measurements were performed in duplicates. The uPA was detected by biotinylated monoclonal antibody to human urokinase followed by the addition of peroxidase-conjugated avidin and 3, 3', 5, 5' -tetramethylbenzidine as substrate. Absorbance was measured at 450 nm by an automated microtitre plate reader (Behring ELISA Processor II, Germany). Recombinant scuPA served as the standard in the uPA ELISA, whose lower limit of detection is 10 pg ml-'. Different forms of uPA such as pro-uPA, HMW-uPA and LMW-uPA were recognised. In addition, uPA complexes with PAI-I or -2, or complexes with the uPA-receptor were detected. Exposure of uPA to various proteases did not affect the determination (Schmitt et al., 1989) .
PAI-I was determined using a commercially available ELISA kit (American Diagnostica type Immubind no. 821). Recombinant PAI-I was used as the standard in the PAI-i ELISA. The lower detection limit of PAI-I ELISA was 50 pg PAI-I ml-'. The assay detected latent (inactive) and active forms of PAI-i and PAI-I complexes. This assay was insensitive to PAI-2.
Vessel staining, grading and counting All vessels were highlighted by staining endothelium cells for CD31 and factor VIII (Dako Diagnostica, Hamburg, Germany) by the use of the APAAP method. Representative areas of the invasive component of the cancer were selected from sections stained with haematoxylin and eosin. Often, these areas contained some in situ carcinoma. Areas of invasive tumour containing the most capillaries and small venules (areas of most intense neovascularisation) were examined by light microscopy. Tumours were frequently heterogeneous in their microvessel density, but the areas of highest neovascularisation were found by scanning the tumour sections at lower power (40 x and 100 x ) and identifying the areas of invasive carcinoma with the highest number of discrete microvessel stainings.
There was no significant difference in vessel density between CD31 and factor VIII staining. To improve the accuracy of microvessel counts determined with the technique used in this study, a second investigator repeated the vessel counts (at 200 x and 400 x ) and grading of the same tumours. He had no previous knowledge of the counts and grades obtained by the first investigator. Although the agreement was not 100% in every case, linear regression showed that the second investigator's counts correlated highly with those of the first one (density-grading correlation coefficient r = 0.87, P<0.01; counts at 200 x r = 0.91, P<0.01, counts at 400 x r = 0.93; angioinvasion counts, r = 0.78, P<0.01) Microvessel counts and density grades were determined without knowledge of the patients' outcome, the presence or absence of metastases or any other pertinent variables.
Statistical analysis
The Wilcoxon-Mann-Whitney U-test (rank-sum test) was used for all statistical analyses. For evaluation of differences in uPA levels of central and peripheral portions of carcinoma we used Wilcoxon's matched pairs signed rank test. Results are expressed as the mean ± standard error of the mean (s.e.m.) and are considered significant at the P<0.05 level (two-tailed). Correlations between uPA, PAI-1, vessel density and vascular invasion counts were calculated by the method of Pearson and Spearman.
Results
The main results are listed in Table I . For the antigens uPA and PAI-I the difference between node-negative and nodepositive patients was statistically significant, although a considerable variation of uPA and PAI-I content was noted. The uPA levels of peripheral tumour areas were significantly higher (4.39 ± 0.53 ng mg-'; P<0.05) than in central breast cancer portions (2.07 ± 0.18). In the case of carcinomas smaller than 1.5 cm (n = 9), the uPA content was 1.93 ± 0.46 ng mg-' in peripheral and 1.90 ± 0.46 ng mg-' in central tumour areas. We found virtually no differences in uPA levels of central tumour areas in patients with and without metastases, but there was a large and statistically significant difference in peripheral tumour parts of the same groups. This result could be confirmed and verified in corresponding histological sections stained for uPA antigen. Another observation in these stainings deserves special emphasis. Tumour cells in high-grade duct carcinoma in situ have a stronger staining for uPA than invasive tumour cells in their vicinity (Figure 2) . We interpreted this powerful staining as a sign of activation of these potentially invasive tumour cells for degrading the basement membrane and becoming invasive.
A moderate correlation between uPA and PAI-I levels exists (r = 0.79); PAI-i is inversely related to steroid hormone receptors (Figure 3 ). PAI-1 may be subject to hormone regulation. This is particularly well established in the case of the inhibitor in the rat hepatoma cell line HCT (Gelehrter et al., 1983) .
The mean microvessel counts in node-positive patients in areas of highest neovascularisation were 92.9 ± 10.5 per 200 x field and 37.9 ± 3.7 per 400 x field. In the tumours of the patients without metastases, the corresponding values were 45.3 ± 4.8 per 200 x field and 25.3 ± 2.1 per 400 x field. The carcinomas of patients with metastases had a mean microvessel density grade of 2.65; the carcinomas of the patients without metastases had a grade of 1.79 (P<0.05).
The average vessel counts were a little higher with CD31 staining than with factor VIII staining. There was a close correlation between CD31 and factor VIII staining, suggesting that both stainings are reliable methods of quantifying angiogenesis in tumour tissues.
The mean of angioinvasion was 3.31 ± 0.48 per 400 x field, which means that 10.2 ± 1.5% of all endothelium cell-lined channels had tumour vessel invasions. The difference between node-negative (7.7 ± 1.4%) and node-positive (11.7 ± 1.9%) patients was significant at the P<0.05 level.
There was a close correlation between vessel density (200 x field) and peripheral uPA level (r = 0.85; P<0.01; 95% confidence interval 0.74-0.91). The correlation was still significant when the patients were separated into nodenegative and node-positive groups (Table II) .
The Ki-67 proliferation rates (23.9 ± 2.7%, n = 42) differ significantly in node-positive (28 ± 3%) and node-negative (19 ± 1.9%) patients (P<0.05). We have found a high correlation between the Ki-67 growth fraction and the uPA levels (r=0.91, P<0.001) (Figure 4) .
The macrophage grading did not differ significantly in node-positive (2.56 ± 0.21) and node-negative (2.05 ± 0.2) patients. In agreement with Muller et al. (1992) , we found a ubiquitous distribution of macrophages and a preponderant localisation within the tumour stroma, but virtually no accumulation around hot spots of vascular proliferation. The macrophages were most frequent and in a high density at the margins of tumour cell islands. Sometimes they were localised within tumour islands (Muller et al., 1992) .
Discussion
This study shows a significant correlation between the uPA and PAI-1 levels of breast cancer tissue extracts and the density of microvessels and vascular invasion in histological sections ( Figure 5 ). It is known that the first step in angiogenesis is a proteolytic degradation of vessel walls, and it is thought that this initiation of neovascularisation is triggered by collagenases, including type IV, and plasminogen activators released by endothelium cells (Mahadevan et al., 1990) . Our results support the hypothesis that uPA and enzymes which disrupt vessel walls start their degradation, and thus neovascularisation, at the exterior vessel side after being released by tumour cells. The enzyme-caused vessel wall dissolution is a known stimulus which leads to a proliferation of endothelium cells, supported by various angiogenic factors, and subsequently to the formation of new blood vessels. Thus uPA and perhaps other proteolytic enzymes released by tumour cells may be involved in the initiation of angiogenesis; uPA may be an indirect angiogenic factor in vivo. Furthermore, the invasive chemotactic behaviour of endothelial cells at the tips of growing capillaries is facilitated by plasminogen activators and collagenases released by tumour cells as well as endothelium cells (Moscatelli et al., 1981) .
On the other hand, proliferating capillaries have fragmented basement membranes and are leaky, making them more penetrable by tumour cells than mature vessels (Nagy et al., 1989) . This may be an important factor which explains our result concerning the tumour vessel invasion. Tumours possessing high levels of uPA have 9% more vascular invasions than carcinomas with an uPA level lower than 3 ng mg-'. This entry of tumour cells into circulation is the beginning of metastatic processes and may explain clinical investigations concerning uPA and breast cancer.
The fact that plasminogen activators are indispensable for tube formation of microvascular cells, and that they may induce angiogenesis in vitro (Yasunaga et al., 1989; Sato et al., 1993) , strongly suggests a role for uPA in tumour neovas- Figure 6 ). Thus the tumour cell entry into circulation may happen more frequently at an early time, and it is this early tumour dissemination which leads to a shortened overall survival time.
An important result of this study is that central portions of breast carcinoma contain less uPA antigen than peripheral tumour parts. This was confirmed by the evaluation of histological sections stained for uPA antigen (Figures 7 and 8 ). This agrees with other authors who have found that in Lewis lung carcinoma uPA was located in the invading parts of the tumour, often in areas in which active infiltration and tissue destruction was taking place (Skriver et al., 1984) . This is in agreement with the fact that the areas of high neovascularisation were most frequent at the margins of the carcinoma. This heterogeneous distribution of uPA in breast cancer suggests that the tissue used for extraction should be taken at the tumour margins.
On the other hand, we did not find significant differences in uPA levels in central compared with peripheral tumour portions in carcinomas smaller than 1.5 cm. This may be explained by the difficulty in distinguishing between central and peripheral areas during tissue extraction and more likely the entire tumour tissue is the area of active infiltration and tissue destruction, so that in this confined group of small tumours the uPA content seems to be homogeneously distributed.
PAI-I correlates weakly with uPA and with vessel density. It seems somewhat contradictory that the uPA inhibitor PAI-1 is also important for poor prognosis and that its ranking in multivariate analysis is close in order to that of uPA (Jinicke et al., 1991) , since one would expect PAI-I to act protectively by blocking the enzymatic activity of free and receptorbound uPA. Jinicke et al. argued that excess release of PAI-1 might be of importance for reimplantation of circulating tumour cells, since formation of new stroma at the metastatic site requires the blockade of uPA-mediated degradation of extracellular matrix.
It was hypothesised that PAI-I levels in tumour extracts may be a biochemical measure of the extent of neovascularisation (Grondahl-Hansen et al., 1993) , since PAI-l may play a role in angiogenesis (Montesano et al., 1990) . 
